Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
92 Cards in this Set
- Front
- Back
how are primidines absorbed/salvaged
|
at the nucleoside level
|
|
describe how dTTP is synthesized, from what precursor, and why in this method
|
dUTP > dUMP > dTMP > dTTP; keep dUTP low because DNA polymerase cannot distinguish between dUTP/dTTP
|
|
describe the effect of 5-fluoro-uracil
|
used as an anti-cancer agent; 5FU salvaged to dUMP and inhibits thymidylate synthase, preventing synthesis of thymidine and inhibiting DNA synthesis in proliferating cells
|
|
describe the mechanism of DHF reductase-inhibitors
|
thymidine synthesis requires THF, and DHF recycled to THF, so lack of THF inhibits thymidine synthesis > inhibit DNA synthesis
|
|
describe THF/B12 interaction in primary folate metabolic pathway
|
THF donates group to B12 to make it active > active B12 donates CH3 group to homocysteine to make methionine > methionine can be converted to SAM
|
|
what is the function of SAM
|
methyl group donor, metabolic pathways
|
|
what compound can build up with folate/B12 deficiency, what is the risk
|
homocysteine; increased risk of CV disease
|
|
list four anti-metabolite drugs
|
1. acyclovir, 2. AZT, 3. cytosine arabinose, 4. 6-mercaptopurine
|
|
which anti-metabolite can be used against HIV
|
AZT (affects viral DNA polymerase)
|
|
describe difference between anterior/posterior pituitary secretions
|
posterior pituitary secretes oxytocin/vasopressin (ADH) from neurons; anterior pituitary secretes from its own cells under control by hypothalamus (secrete ACTH, FSH/LH/TSH, GH, prolactin)
|
|
what is the precursor molecule for ACTH, what else can ACTH break down to
|
POMC; ACTH and POMC can be broken down into MSH (melanocyte stimulating hormone) that can darken skin by stimulating melanocytes
|
|
what are positive/negative releasing factors for GH (growth hormone)
|
somatostatin inhibits; GHRH stimulates
|
|
what are positive/negative releasing factors for FSH/LH, TSH
|
GnRH and TRH
|
|
what are positive/negative releasing factors for prolactin
|
dopamine
|
|
list two ways GH can exert its actions
|
1. directly on tissue, 2. secondary pathway, producing IGF1
|
|
what are primary effects of GH
|
1. stimulating growth of long bones, 2. increase metabolic, cell proliferation, 3. stimulating osteoblast/osteoclast activity and proliferation
|
|
how does long bone elongation occur
|
GH stimulates chondrocyte proliferation and maturation > epiphyseal cartilage plate moves up and cartilage below is replaced with calcified bone (increased secretion of matrix)
|
|
what are the three primary bone-related cells, and their origin
|
1. chondrocyte (mesenchymal), 2. osteoblast (mesenchymal), 3. osteoclast (macrophage)
|
|
list two causes of excessive GH
|
1. tumor of pituitary/hypothalamus; 2. ectopic tumor, usually at lung
|
|
two conditions that excessive GH can cause
|
1. acromegaly -- occurs after closure of epiphyseal plate; thickening of skin, enlarged hands; 2. gigantism -- very tall, can lead to acromegaly
|
|
define laron syndrome
|
defect in GH receptor
|
|
define idiopathic short stature
|
normal GH levels, but insufficient for normal growth; can supplement with GH to grow taller
|
|
two primary sources of GH deficiency
|
1. congential, due to defect in GH/receptor/etc; 2. acquired, due to tumor/trauma
|
|
describe pathogenesis of graves' disease
|
hyperactive synthesis of TH, caused by antibody autoimmune reaction on TSHr
|
|
what happens when TSH binds to thyroid
|
1. stimulates insertion/synthesis of Na/I symporter channels; 2. increase synthesis of thyroglobulin; 3. increase thyroid peroxidase activity
|
|
what is the primary amino acid in TH
|
tyrosine
|
|
what is thyroid peroxidase
|
oxidizes iodine so it can be coupled with thyroglobulin
|
|
describe pathway of TH synthesis
|
1. TSH stimulates synthesis, 2. iodine is oxidized, 3. thyroglobulin and iodine are coupled, 4. stored as Tg-T4/Tg-T3, 5. secretion requires cleaving off Tg
|
|
what is the primary thyroid hormone released
|
T4 (thyroixine)
|
|
characteristics of T3 vs T4
|
T3 is more potent, but much shorter half-life than T4; in tissues T4 will be converted to T3
|
|
describe activation/inactivate of thyroid hormone
|
D1 (thyroid/liver) converts to T3 (regulated by T3); D2 (brain, other cells, pituitary) provides rapid T3 production; D3 -- for inactivation of T4 or inactivation of T3
|
|
describe consumptive hypothyroidism
|
hyperactivity of D3 > hyperactive inactivation of TH
|
|
in what state is most of TH in bloodstream
|
bound to thyroxine binding protein
|
|
how is TH level regulated
|
free T3/T4 inhibit secretion of TSH from the anterior pituitary gland (contains D2)
|
|
how is thyroid hormone levels assessed
|
TSH level, sometimes get T3/T4 assay
|
|
what assays can be performed to assess graves' disease
|
look for antibody against TSHr or thyroxine binding protein
|
|
how does T3 exert its metabolic effects
|
binds to thyroid response element to affect gene regulation
|
|
pathogenesis of creatinism
|
extreme hypothyroidism (iodine, gland) leading to mental retardation and failure to grow
|
|
what is congential hypothyroidism
|
defective thyroid (no thyroid gland) or defective TH
|
|
what are signs of hypothyroidism (blood tests)
|
elevated TSH, normal or low T3/T4; normal T3/T4 presented in subclinical hypothyroidism
|
|
pathogenesis of hashimoto's disease
|
autoimmune attack against thyroid cells, causing hypothyroidism
|
|
how is hypothyroidism treated
|
administration of T4, levothyroxine
|
|
what are some clinical signs of graves' disease
|
bug-eyed, sleep disturbance, tremors, goiter
|
|
what is treatment for graves' disease
|
anti-thyroid substances or surgery
|
|
pathogenesis of subacute thyroiditis
|
inflammation/destruction of follicles causes hyperthyroidism > hypothyroidism after TH is depleted > resolves on its own in most patients
|
|
list two types of goiters
|
1. cold nodules, hypofunctioning, should be removed; 2. hot nodules, hyperactive, but usually benign
|
|
what is thiazide effect on calciium absorption
|
increases calcium absorption
|
|
describe Ca2+ transport in bloodstream
|
half ionized form, half are protein-bound
|
|
what are two mechanisms of Ca2+ regulation and sites of function
|
1. PTH (affects kidney/bone), 2. 1,25(D) (affects absorption at intestine)
|
|
where is Ca2+ sensor located
|
on parathyroid gland and on kidney
|
|
describe mechanism of Ca2+ sensing
|
increase in free-Ca2+ > decrease PTH secretion; at the kidney, high Ca2+ will reduce absorption of Ca2+
|
|
describe activating mutations of Ca2+ sensor
|
cell thinks it is always high Ca2+ > leads to low PTH > hypocalcemia
|
|
describe inactivating mutations of Ca2+ sensor
|
feedback is dampened > PTH is high > 1. hypercalcemia in blood serum, 2. kidney retain Ca2+ because cannnot sense hypercalcemia, so low urine Ca2+
|
|
list four functions of PTH
|
1. bone resorption, 2. increase renal Ca2+ absorption, 3. decrease renal PO4- absorption, 4. increase formation of active 1,25(D)
|
|
describe bone resorption mechanism of PTH
|
PTH binds osteoblast > express RANKL ligand > activates osteoclast
|
|
where is the site of renal PTH regulation
|
distal tubule
|
|
describe vitamin D metabolism
|
sunlight UVB activates vitD > liver converts to 25(D) > kidney converts to 1,25(D), this step requires PTH > vitD binds to vitD receptor > modulates gene transcription > 1. increase intestinal Ca2+ absorption, 2. increase bone resorption
|
|
how is vitamin D measured
|
measure 25(D) form, calcidiol, because 1,25(D) calcitriol has short half-life
|
|
describe body response to low Ca2+
|
1. secretion of PTH, 2a. renal Ca2+/PO4 absorption change, 2b. increase 1,25(D) > increase intestinal absorption of Ca2+, 2c. increase bone resorption
|
|
describe body response to low PO4
|
1. increase 1,25(D), 2a. feedback to decrease PTH > decrease renal Ca2+ absorption, 2b. increse bone desorption, 2c. increase intestine PO4/Ca2+ absorption and renal PO4 reabsorption
|
|
what are typical symptoms of hypercalcemia
|
asymptomatic, thirst, constipation, renal stones
|
|
three primary causes of hypercalcemia
|
1. malignant bone tumor, secretes PTH-related peptide which functions similarly to PTH; 2. vitamind D intoxication; 3. renal reabsorption, due to familial hypocalciuric hypercalcemia OR thiazides
|
|
what is PTH-related peptide
|
required for normal bone development as a paracrine hormone, but tumors elevate blood [PTH-rp] to detectable levels
|
|
explain cause for four levels high/low PTH vs high/low Ca2+
|
1. high PTH/Ca2+ -- hyperparathyroidism; 2. high PTH, low Ca2+ -- PTH not working; 3. low PTH, high Ca2+ -- tumor secreted PTH-rp; 4. low PTH, low Ca2+ -- hypoparathyroidism
|
|
describe pathogenesis of primary hyperparathyroidism
|
overactive parathyroid gland; long-term will develop calcifications
|
|
what effect does hypocalcemia have on nerves
|
increases excitability
|
|
what is trousseau sign
|
contraction due to hypoxia and hypocalcemia; place BP cuff over arm to witness contracture of hand
|
|
what is chvostek sign
|
observation of hyperstimulation of the facial nerve due to hypocalcemia (tap on the side of head)
|
|
what are symptoms of hypocalcemia
|
trousseau sign, chvostek sign, seizures
|
|
what are some causes of hypocalcemia
|
1. low Mg2+ (need for PTH function and vitamind D function); 2. low or defective PTH; 3. renal failure (leads to high PO4 and low 1,25(D)); 4. high PO4 (lowers Ca2+ and inhibits 1,25(D) synthesis)
|
|
classic sign of albright's hereditary osteodystrophy
|
shortened 4th metacarpel, short stature
|
|
how does presentation of a cervical hump occur
|
osteoporosis causing bone loss in the spine
|
|
what is the primary result of osteoporosis
|
decreased bone mass and bone matrix, causing increased risk of vertebral and compression fractures
|
|
describe pathogenesis of osteomalacia
|
defective bone mineralization of osteoid, resulting in softening of bones; caused by deficient vitamin D
|
|
define genu valgum and genu varus, in what pathology
|
rickets, bowing of the legs inward and outward
|
|
which gland secretes androgens in male/female
|
male -- testes; female -- adrenal glands
|
|
what is the precursor molecule for steroid hormone synthesis
|
cholesterol
|
|
describe how steroids exert their effects on cells
|
steroid hormone diffuses into cytoplasm > binds cytoplasmic receptor > translocate to nucleus to bind DNA motifs
|
|
describe general steroid synthesis
|
1. adrenal cell lipase convert lipid/cholesterol esters to free cholesterol; 2. desmolase converts cholesterol to pregnenolone; 3. each cell has different enzyme to make different steroid
|
|
describe what each region of the adrenal gland makes (outer to inner)
|
1. zona granulosa : aldosterone; 2. zona fasciculata : cortisol; 3. zona reticularis : androgens/sex steroids (synthesize a precursor, then transported to gonads to be converted to testosterone/estrogen)
|
|
describe synthesis, binding of cortisol, and sites of negative feedback
|
1. hypothalamus secrete CRH > anterior pituitary secrete ACTH; 2. ACTH drives lipase/desmolase to secrete cortisol (zona fasciculata); 3a. cortisol binds to cytoplasmic glucocorticoid receptors > translocate into nucleus; 3b. negative feedback at hypothalamus and pituitary
|
|
what are the primary effects of cortisol
|
1. increases blood glucose/fatty acid; 2. increase protein catabolism and lipolysis
|
|
describe pathogenesis of congenital adrenal hyperplasia
|
defective 21-hydroxylase (most common) > a. no synthesis of aldosterone/cortisol, b. shunt to testosterone; effects -- ambigious genitalia in female, precocious puberty in males
|
|
what happens to ACTH levels in congenital adrenal hyperplasia
|
extremely high due to low cortisol
|
|
what signal stimulates aldosterone synthesis
|
angiotensin II
|
|
describe synthesis and binding of aldosterone
|
1. decreased BP stimulates release of renin; 2. converted to AngI and AngII; 3a. SMC vasoconstriction; 3b. stimulate synthesis of aldosterone; 4. binds to cytoplasmic mineralcorticoid receptors; 5. increase synthesis of Na+ channels
|
|
explain effect of elevated cortisol on aldosterone
|
cortisol can mind to same mineralcorticoid receptors
|
|
how is cortisol degraded, how can pathology develop
|
degraded by dehydrogenase; licorice/tobacco inhibits dehydrogenase, or defective dehydrogenase, leads to hyperstimulation of mineralcorticoid receptors > hypertension
|
|
treatment options of defective cortisol dehydrogenase
|
ACE inhibitor, aldosterone anatagonist, AngII antagonist
|
|
explain pathway of GH synthesis and action
|
1. GHRH stimulates GH synthesis/release, transported on GH-binding protein; 2a. bind to liver > secrete IGF and IGF-binding protein (endocrine), 2b. bind tissue > secrete IGF (autocrine); 3. bind to IGF receptor > growth
|
|
what are negative feedback mechanisms for GH synthesis
|
GH inhibits GH release; GH stimulates somatostatin release, which inhibits GH release
|
|
what are metabolic effects of GH
|
increased amino acid uptake; increased protein/DNA/RNA synthesis; decreased glucose uptake
|